Communications and Marketing

Communications and Marketing

Head of Communications and Marketing

Ulrike Grönefeld

Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 422854

Press Officer

Dr. Sibylle Kohlstädt

Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 422843

Recent Press Releases

No. 03 | 16. January 2019 | by Eck

Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice

Computer-generated simulation of a HPV

Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists' goal is to develop a therapeutic vaccine for people who are already suffering from cancer or cancer precursors and, thus, no longer benefit from preventive vaccination.

learn more

No. 02c2 | 15. January 2019

“Life Time” – European research for a healthier future

© Spencer Phillips, EMBL-EBI

Our body's cells are constantly changing. But which of these changes are healthy developments and which lead to serious diseases? This is what LifeTime, a new transnational and interdisciplinary initiative of leading European researchers, aims to discover. The consortium is jointly coordinated by the Max Delbrück Center in Berlin and the Institut Curie in Paris, with the Helmholtz Association and the CNRS. Scientists from the DKFZ are also involved in the consortium. Life Time has now cleared an important hurdle: The consortium will be given one million euros and one year to develop a plan to embed its vision for a healthier future within the European research and innovation landscape.

learn more

No. 02 | 08. January 2019 | by Rei

New vaccine strategy against Epstein Barr virus

Epstein Barr viruses in blood vessels
© Adobe Stock/DKFZ

The Epstein Barr viruses (EBV) are very common and in most cases, an infection causes no harm. However, sometimes the outcome is a serious disease. There is no effective immunization protection against EBV so far, because the pathogen is very difficult to get hold of. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now developed a new strategy for developing a vaccine against EBV that will simultaneously prepare the immune system for different stages of the pathogen. In this way, the researchers are convinced to have made major progress towards developing a vaccine against EBV.

learn more


einblick (in German only)


Subscribe to our RSS-Feed.

to top